Cardiovascular disease in patients with chronic human immunodeficiency virus infection

International Journal of Cardiology

Volumn 175, Issue 1, 2014, Pages 1-7

  Escárcega, Ricardo O ^a   Franco, Joseph J ^a   Mani, Bhalaghuru Chokkalingam ^a   Vyas, Apurva ^a   Tedaldi, Ellen M ^b   Bove, Alfred A ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiomyopathy; Cardiovascular disease; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE THERAPY; DRUG SAFETY; DYSLIPIDEMIA; ECG ABNORMALITY; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEFT VENTRICULAR ASSIST DEVICE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; REVIEW; RISK REDUCTION; SUDDEN DEATH; SURVIVAL RATE; UNITED NATIONS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DRUG INTERACTION; HIV INFECTIONS; METABOLISM; PHYSIOLOGY;

ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS;

EID: 84902533733     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.04.155     Document Type: Review

References (79)

1. UNAIDS report on the global AIDS epidemic http://www.unaids.org/en/media/ unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global- Report-2012-en.pdf
2. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies Clin Infect Dis 50 2010 1387 1396
3. R.B. Effros, C.V. Fletcher, and K. Gebo et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions Clin Infect Dis 47 2008 542 553
4. M. Saves, G. Chene, and P. Ducimetiere et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population Clin Infect Dis 37 2003 292 298
5. L.H. Kuller, R. Tracy, and W. Belloso et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection PLoS Med 5 2008 e203
6. L. ao, O. Herlea-Pana, J. Heuser-Baker, Y. Chen, and J. Barlic-Dicen Roles of the chemokine system in development of obesity, insulin resistance and cardiovascular disease J Immunol Res. 2014 2014 181450
7. R.O.G.-C.M. Escarcega, L.J. Jara, and R. Cervera Accelerated Atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality Lupus 18 2009 383 386
8. F.L.S. Boccara, C. Meuleman, and S. Ederhy et al. HIV and coronary heart disease: time for better understanding J Am Coll Cardiol 61 2013 511 523
9. F. Boccara, S. Lang, and C. Meuleman et al. HIV and coronary heart disease: time for a better understanding J Am Coll Cardiol 61 2013 511 523
10. R.C. Kaplan, L.A. Kingsley, and A.R. Sharrett et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women Clin Infect Dis 45 2007 1074 1081
11. M. Baekken, I. Os, L. Sandvik, and O. Oektedalen Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy J Hypertens 26 2008 2126 2133
12. J. Capeau From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging Curr Opin HIV AIDS 2 2007 247 252
13. C. Gazzaruso, R. Bruno, and A. Garzaniti et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome J Hypertens 21 2003 1377 1382
14. S.K. Grinspoon Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus Am J Med 118 Suppl. 2 2005 23S 28S
15. G. d'Ettorre, M. Francone, and M. Mancone et al. Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects J Infect 64 2012 82 88
16. M. Rotger, T.R. Glass, and T. Junier et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons Clin Infect Dis 57 2013 112 121
17. R. Perello, M. Calvo, and O. Miro et al. Clinical presentation of acute coronary syndrome in HIV infected adults: a retrospective analysis of a prospectively collected cohort Eur J Intern Med 22 2011 485 488
18. F. D'Ascenzo, E. Cerrato, and G. Biondi-Zoccai et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy Eur Heart J 33 2012 875 880
19. F. Boccara, M. Mary-Krause, and E. Teiger et al. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis Eur Heart J 32 2011 41 50
20. A. Knudsen, A.B. Mathiasen, and R.H. Worck et al. Angiographic features and cardiovascular risk factors in human immunodeficiency virus-infected patients with first-time acute coronary syndrome Am J Cardiol 111 2013 63 67
21. R.G. Micheletti, G.A. Fishbein, and M.C. Fishbein et al. Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study Cardiovasc Pathol 18 2009 28 36
22. M.V. Zanni, S. Abbara, and J. Lo et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men AIDS 27 2013 1263 1272
23. K.V. Fitch, J. Lo, and S. Abbara et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters J Acquir Immune Defic Syndr 55 2010 495 499
24. W. Khovidhunkit, M.S. Kim, and R.A. Memon et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host J Lipid Res 45 2004 1169 1196
25. K.E. Wellen, and G.S. Hotamisligil Inflammation, stress, and diabetes J Clin Invest 115 2005 1111 1119
26. R.O. Escarcega, M. Garcia-Carrasco, and S. Fuentes-Alexandro et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease Autoimmun Rev 6 2006 48 53
27. X. Ren, M. Trilesskaya, D.M. Kwan, K. Nguyen, R.E. Shaw, and P.Y. Hui Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection Am J Cardiol 104 2009 216 222
28. G. Barbaro Cardiovascular manifestations of HIV infection Circulation 106 2002 1420 1425
29. M. Bijl, J.P. Dieleman, M. Simoons, and M.E. van der Ende Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy J Acquir Immune Defic Syndr 27 2001 318 320
30. G. Barbaro, G. Di Lorenzo, B. Grisorio, and G. Barbarini Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators AIDS Res Hum Retroviruses 14 1998 1071 1077
31. M.A. Silver, A.M. Macher, and C.M. Reichert et al. Cardiac involvement by Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS) Am J Cardiol 53 1984 983 985
32. I.S. Cohen, D.W. Anderson, and R. Virmani et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome N Engl J Med 315 1986 628 630
33. D.G. Blanchard, C. Hagenhoff, L.C. Chow, H.A. McCann, and H.C. Dittrich Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study J Am Coll Cardiol 17 1991 1270 1276
34. K.E. Mondy, J. Gottdiener, and E.T. Overton et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy Clin Infect Dis 52 2011 378 386
35. P.F. Currie, A.J. Jacob, A.R. Foreman, R.A. Elton, R.P. Brettle, and N.A. Boon Heart muscle disease related to HIV infection: prognostic implications BMJ 309 1994 1605 1607
36. G.M. Felker, R.E. Thompson, and J.M. Hare et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy N Engl J Med 342 2000 1077 1084
37. D.S. Fieno, L.S. Czer, E.R. Schwarz, and S. Simsir Left ventricular assist device placement in a patient with end-stage heart failure and human immunodeficiency virus Interact Cardiovasc Thorac Surg 9 2009 919 920
38. D.B. Sims, N. Uriel, and J. Gonzalez-Costello et al. Human immunodeficiency virus infection and left ventricular assist devices: a case series J Heart Lung Transplant 30 2011 1060 1064
39. N. Uriel, U.P. Jorde, and V. Cotarlan et al. Heart transplantation in human immunodeficiency virus-positive patients J Heart Lung Transplant 28 2009 667 669
40. O. Wever-Pinzon, S. Bangalore, J. Romero, J. Silva Enciso, and F.A. Chaudhry Inotropic contractile reserve can risk-stratify patients with HIV cardiomyopathy: a dobutamine stress echocardiography study JACC Cardiovasc Imaging 4 2011 1231 1238
41. R.S. Crow, R.J. Prineas, P.J. Hannan, G. Grandits, and H. Blackburn Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial Am J Cardiol 80 1997 138 144
42. M.L. Daviglus, Y. Liao, and P. Greenland et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study JAMA 281 1999 530 536
43. E.Z. Soliman, R.J. Prineas, and M.P. Roediger et al. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study J Electrocardiol 44 2011 779 785
44. C. van Noord, M. Eijgelsheim, and B.H. Stricker Drug- and non-drug-associated QT interval prolongation Br J Clin Pharmacol 70 2010 16 23
45. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013 1022
46. A.G. Kocheril, S.A. Bokhari, W.P. Batsford, and A.J. Sinusas Long QTc and torsades de pointes in human immunodeficiency virus disease Pacing Clin Electrophysiol 20 1997 2810 2816
47. M.U. Sani, and B.N. Okeahialam QTc interval prolongation in patients with HIV and AIDS J Natl Med Assoc 97 2005 1657 1661
48. B. Damle, C. Fosser, and K. Ito et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study J Clin Pharmacol 49 2009 291 300
49. N. Sarapa, D.J. Nickens, S.R. Raber, R.R. Reynolds, and M.A. Amantea Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies Clin Pharmacol Ther 83 2008 153 159
50. E.Z. Soliman, J.D. Lundgren, and M.P. Roediger et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations AIDS 25 2011 367 377
51. K. Hunt, C.A. Hughes, and C. Hills-Nieminen Protease inhibitor-associated QT interval prolongation Ann Pharmacother 45 2011 1544 1550
52. R.C. Owens Jr. QT prolongation with antimicrobial agents: understanding the significance Drugs 64 2004 1091 1124
53. G. Vallecillo, S. Mojal, and A. Roquer et al. Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy Clin Infect Dis 57 2013 1189 1194
54. S.S. Chugh, J. Jui, and K. Gunson et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community J Am Coll Cardiol 44 2004 1268 1275
55. Z.J. Zheng, J.B. Croft, W.H. Giles, and G.A. Mensah Sudden cardiac death in the United States, 1989 to 1998 Circulation 104 2001 2158 2163
56. D.W. Dowdy, E.H. Geng, and K.A. Christopoulos et al. Mortality among antiretroviral-eligible patients in an urban public clinic J Acquir Immune Defic Syndr 57 2011 297 300
57. Z.H. Tseng, E.A. Secemsky, and D. Dowdy et al. Sudden cardiac death in patients with human immunodeficiency virus infection J Am Coll Cardiol 59 2012 1891 1896
58. N.T.H. Obel, G. Kronborg, C.S. Larsen, P.R. Hildebrandt, H.T. Sørensen, and J. Gerstoft Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study Clin Infect Dis 44 2007 1625 1631
59. K.A. Freedberg, E. Losina, and M.C. Weinstein et al. The cost effectiveness of combination antiretroviral therapy for HIV disease N Engl J Med 344 2001 824 831
60. M.A. Thompson, J.A. Aberg, and J.F. Hoy et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society - USA panel JAMA 308 2012 387 402
61. M. Ray, R. Logan, and J.A. Sterne et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals AIDS 24 2010 123 137
62. M.S. Cohen, Y.Q. Chen, and M. McCauley et al. Prevention of HIV-1 infection with early antiretroviral therapy N Engl J Med 365 2011 493 505
63. C.I. Okwundu, O.A. Uthman, and C.A. Okoromah Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals Cochrane Database Syst Rev 7 2012 CD007189
64. N. Friis-Moller, R. Weber, and P. Reiss et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study AIDS 17 2003 1179 1193
65. M. Mary-Krause, L. Cotte, A. Simon, M. Partisani, and D. Costagliola Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men AIDS 17 2003 2479 2486
66. Thienemann F, Sliwa K, Rockstroh JK. HIV and the Heart: the impact of antiretroviral therapy; a global perspective. Eur Heart J;34: 3538-3546.
67. S.A. Bozzette, C.F. Ake, and H.K. Tam et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy J Acquir Immune Defic Syndr 47 2008 338 341
68. A. Carr, K. Samaras, and S. Burton et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 1998 F51 F58
69. G. Barbaro Heart and HAART: two sides of the coin for HIV-associated cardiology issues World J Cardiol 2 2010 53 57
70. P.Y. Hsue, J.C. Lo, and A. Franklin et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection Circulation 109 2004 1603 1608
71. G. Iacobellis, A.M. Pellicelli, and B. Grisorio et al. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat Obesity (Silver Spring) 16 2008 179 183
72. G. Iacobellis, A.M. Pellicelli, A.M. Sharma, B. Grisorio, G. Barbarini, and G. Barbaro Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus Am J Cardiol 99 2007 1470 1472
73. K.A. Lichtenstein, C. Armon, and K. Buchacz et al. Low CD4 + T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study Clin Infect Dis 51 2010 435 447
74. D.K. Shirley, R.K. Kesari, and M.J. Glesby Factors associated with smoking in HIV-infected patients and potential barriers to cessation AIDS Patient Care STDS 27 2013 604 612
75. S.I. Rennard, and D.M. Daughton Smoking cessation Clin Chest Med 35 2014 165 176
76. FDA drug safety communication: new restrictions, contraindications, and dose limitations for zocor (simvastatin) to reduce the risk of muscle injury june 8th 2011 (http://www.fda.gov/drugs/drugsafety/ucm256581.htm). Accessed online February 2014
77. A.J. Busti, A.M. Bain, and R.G. Hall II et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin J Cardiovasc Pharmacol 51 2008 605 610
78. G.A. Schmidt, J.D. Hoehns, J.L. Purcell, R.L. Friedman, and Y. Elhawi Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir J Am Board Fam Med 20 2007 411 416
79. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2013 Nov 7 10.1016/j.jacc.2013.11.002 (Epub ahead of print)